Over 20 partnering meetings held in Europe; expanding therapeutic scope to non-hepatic tissues.
SRN001 Phase 1b clinical trial underway; licensing deal to be pursued following data acquisition.
Bioneer is leveraging its proprietary RNA interference (RNAi) platform to pursue global technology licensing agreements. Unlike existing RNAi therapies that primarily focus on liver diseases, the company is executing a strategy to expand its therapeutic reach to organs such as the lungs and kidneys.
According to Bioneer on the 20th, the company conducted approximately 20 partnering meetings with global pharmaceutical firms and major European hospitals during 'BIO-Europe 2026,' held in Cologne, Germany, from the 9th to the 11th.
Its core technology, 'SAMiRNA,' is designed to suppress the expression of specific genes involved in disease progression. The company is utilizing this platform to develop treatments for pulmonary fibrosis and hair loss.
Phase 1b Clinical Trial for Pulmonary Fibrosis Drug; Licensing Success is Key
The lead drug candidate, 'SRN001,' is being developed to treat Idiopathic Pulmonary Fibrosis (IPF), a condition where lung tissue gradually hardens, leading to impaired respiratory function.
The drug works by inhibiting the production of the Amphiregulin (AREG) protein, which is involved in fibrosis, thereby slowing disease progression. Having completed a Phase 1a clinical trial in Australia, the company is currently conducting a Phase 1b multiple-ascending dose study in healthy adults.
Bioneer plans to formalize technology licensing discussions with global pharmaceutical companies once clinical data is secured.
In addition to these efforts, the company has commercialized 'CosmeRNA,' a scalp care product utilizing RNAi technology, and is pursuing the development of a new hair loss treatment. In the field of molecular diagnostics, the company has discussed local clinical evaluation plans for diagnostic equipment and reagents with three major European hospitals.
For the first three quarters of this year, Bioneer reported consolidated revenue of 261.2 billion KRW, a 4.4% increase compared to the same period last year. However, operating profit shifted from a 12.5 billion KRW surplus to a 3.4 billion KRW deficit, as increased sales commissions and R&D expenditures weighed on profitability.
With approximately 93% of current revenue derived from its probiotics business, diversifying its portfolio through successful drug development remains a critical task. The acquisition of SRN001 clinical data and the potential signing of global licensing agreements are expected to be the key variables in determining the valuation of its pharmaceutical business.







